with 40 μg/mL
of SARS-CoV-2 S1 protein produced in-house by incubating for 1 h at
RT. The antigen solution was replaced with PVOH 0.1 mg/mL for 2 h
at RT and then a blocking buffer (Superblock + 10% FBS + 5% GS) and
subsequently stored at 4 °C in the blocking buffer prior to cutting
47 mm long test strips fitted into siphon holders. The seroreactivity
against the ″S1″ antigen was measured using a conventional
endpoint titer protocol, with plasma derived from whole blood volunteer
samples stabilized in 4% sodium citrate (Sigma Aldrich, UK) serially
diluted in the Seablock blocking buffer (ThermoFisher Scientific,
UK). The patient samples were incubated for 10–20 min in the
siphon devices followed by three washes with PBS-T totaling 5 min.
The secondary antibody, anti-human IgG conjugated with alkaline phosphatase
(ThermoFisher Scientific UK) at 1 μg/mL in the Seablock blocking
buffer, was incubated for a total of 10–20 min before being
washed three times with PBS-T allowing a 5 min total wash duration
and then addition of fluorescence substrate.